Published on
November 29, 2021

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients

VANCOUVER, BC, Nov. 29, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compound screening. The testing, which was developed and validated in-house, will be available as part of its service offerings for third-party clients and used for evidence-based conversations with the regulators.

As a global leader in psychedelics testing Numinus Bioscience continues to make strides in the development of analytical testing methods for the psychedelics industry. Amongst the matrices for which methodologies are being developed are Psilocybe mushroom fruiting bodies, extracts, and derivatives and, coupled with required testing such as contaminants and residues, the lab has validated methods for active constituents.  The Psilocybe mushrooms constituent screen includes Psilocybin, Psilocin, Baeocystin, Norbaeocystin and Tryptophan, Norpsilocin and Aeruginascin which represent the most well-defined alkaloids for Psilocybe species.

"The testing we've developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and ultimately the industry," says Sharan Sidhu, Science Officer and General Manager. "Working with regulators, we look forward to establishing tools to create a stronger foundation of analytical methods for psychedelic compounds and products."

In addition to screening for therapeutically active constituents, the lab has successfully developed a psychedelic mushroom toxicity screen that includes nephrotoxic and hepatotoxic compounds. Although the platform has been developed for industry, the screen can quickly identify toxins from several varied species and is being offered to healthcare providers to identify toxins in poison control responses, demonstrating the value of this research beyond the psychedelic industry. Toxicity scans are completed using the Orbitrap, a state-of-the-art, industry leading high resolution mass spectrometry instrument.

"These in-house validated methods are another example of success in analytical development at Numimus, showing our commitment to strengthen regulatory confidence in these products," says Payton Nyquvest, CEO and Founder, Numinus. "We continue to push the boundaries as we establish our role as The Center of Excellence for Psychedelic Research and Development, with the furtherment of the industry at the heart of our advancements."

The research team has thus far characterized over 260 compounds, many of them characterized for the first time in psychedelic mushrooms and continues to make novel discoveries in research and development of Psilocybin. Numinus Bioscience also continues to build testing capabilities for Ketamine, LSD, Mescaline, DMT and MDMA.

About Numinus
Numinus Wellness (TSXV: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", , "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's limited operating and profitability track record; dependence on management; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.